Swiss National Bank
OREX

Swiss National Bank’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Swiss National Bank’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-22,180
Closed -$120K – 2661
2016
Q1 		$120K Buy
22,180
+7,620
+52% +$99K ﹤0.01% 2595
2015
Q4 		$250K Hold
14,560
– – ﹤0.01% 2538
2015
Q3 		$307K Buy
14,560
+2,010
+16% +$68.9K ﹤0.01% 2392
2015
Q2 		$621K Buy
12,550
+440
+4% +$26.3K ﹤0.01% 2103
2015
Q1 		$948K Hold
12,110
– – ﹤0.01% 1791
2014
Q4 		$734K Buy
12,110
+720
+6% +$36.2K ﹤0.01% 1917
2014
Q3 		$485K Buy
11,390
+900
+9% +$48.3K ﹤0.01% 2124
2014
Q2 		$648K Hold
10,490
– – ﹤0.01% 2000
2014
Q1 		$682K Buy
10,490
+2,390
+30% +$162K ﹤0.01% 1945
2013
Q4 		$456K Buy
8,100
+280
+4% +$15.7K ﹤0.01% 2043
2013
Q3 		$480K Buy
7,820
+510
+7% +$34.5K ﹤0.01% 1963
2013
Q2 		$428K Buy
+7,310
New +$450K ﹤0.01% 2023

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Swiss National Bank's OREX Position: Q2 2016 in Review

Swiss National Bank sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2016, closing a stake of 22,180 shares — an estimated $120K sold.

Swiss National Bank first reported a position in OREX in Q2 2013 and held it in 12 quarters. The position peaked at $948K in Q1 2015. 73 funds tracked by Wall St. Rank hold OREX as of Q2 2016.

  • Swiss National Bank reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • Swiss National Bank sold 22,180 Orexigen Therapeutics, Inc. shares in Q2 2016, an estimated $120K.
  • Swiss National Bank first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 12 quarters.
  • Swiss National Bank's Orexigen Therapeutics, Inc. position peaked at $948K in Q1 2015.
  • 73 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2016.

Based on Swiss National Bank's 13F filing for Q2 2016, filed 3 Aug 2016.